CClinicalTrials.gg
Status unknownNCT04237311Updated Mar 11, 2021

Bariatric Surgery and Male Reproductive Function

An observational study in Obesity, Diabetes Mellitus, Type 2 and Bariatric Surgery Candidate, sponsored by The Third Xiangya Hospital of Central South University. Status unknown at 1 site in China. Open to male participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-03-11.

Sponsored by The Third Xiangya Hospital of Central South University · Observational

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
20 Years to 60 Years
Sex
Male
01

Study summary

Obesity is a global public health problem. According to literature reports, as of 2016, China's obese population has reached more than 90 million and type 2 diabetes mellitus has reached more than 100 million, which has brought a serious health and economic burden to China. In addition to various health problems such as cardiovascular, osteoarthritis, and tumors, obesity can also cause abnormalities in reproductive endocrine. In women, it can cause abnormal menstruation, polycystic ovary syndrome, and male obesity can cause secondary gonadal. Hypofunction (MOSH). MOSH is an endocrine dysfunction. It is reported to have a prevalence of approximately 45% in moderate to severe obesity. In addition, studies have pointed out that the prevalence of hypogonadism in men with type 2 diabetes and obesity higher. However, there are no studies on the reproductive function of Chinese male patients after bariatric surgery. Pre- and post-operative semen will be collected for analysis to observe the effect of bariatric surgery on male reproductive function.

02

Conditions studied

  • Obesity
  • Diabetes Mellitus, Type 2
  • Bariatric Surgery Candidate
  • Roux en Y Gastric Bypass
  • Sleeve Gastrectomy

Keywords

  • Semen
  • Micronutrient
  • Inflammation
  • Nutrition
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's planned enrollment of 30 is below the median of 300 across 1,588 observational studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

The Third Xiangya Hospital of Central South University is the lead sponsor of 95 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

bariatric surgery male candidate

Inclusion criteria

  • Meet the surgical indications according to the Chinese Guidelines for Surgical Treatment of Obesity and Type 2 Diabetes (2019 Edition).
  • 20 years old\< patient\<60 years old.
  • Male

Exclusion criteria

Exclusion Criteria:

  • Incapacity of giving an informed consent.
  • Drug and / or alcohol abuse.
  • Scrotal injury and previous scrotal surgery.
  • Use of phosphodiesterase-5 inhibitors.
  • Mental illnesses that may affect compliance with clinical research, including dementia, active psychosis, major depression, or attempted suicide.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Interventions

  • ProcedureSleeve gastrectomy

    Laparoscopic sleeve gastrectomy is performed as following: after greater curvature dissociating, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using linear cutting stapler of 3.5- or 4.8-mm-high staples, depending on gastric thickness.

  • ProcedureRoux-en-Y gastric bypass

    Laparoscopic Roux-en-Y gastric bypass is performed as following: a gastric pouch of approximately 30mL was obtained using linear cutting stapler, the sum of the length of the alimentary limb and the biliopancreatic limb\> 200 cm (can be adjusted according to the incidence of the patient's BMI, type 2 diabetes mellitus and the specific situation).

06

What researchers measure

Primary outcomes

  1. Semen quality assessment

    Semen quality assessment based the following indicators, including the time of liquefaction, semen PH, semen volume, sperm numbers, sperm vitality, sperm motility, sperm morphology, concentration of zinc in seminal plasma, concentration of fructose in seminal plasma, concentration of neutral α-glucosidase in seminal plasma, concentration of seminal elastase.The corresponding detection method is based on WHO laboratory manual for the Examination and processing of human semen(FIFTH EDITION).

    Time frame: 3 months after surgery

Secondary outcomes

  1. Concentration of interleukin in plasma

    interleukin 6, interleukin 8, tumor necrosis factor-α

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  2. Change of body mass index Body constant

    Body mass index=weight(kg)/ height(m2)

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  3. Changes of Vitamins

    Vitamin A, Vitamin B1, Vitamin B2, Vitamin B9, Vitamin B12, Vitamin C, Vitamin D. Folic acid; Vitamin E.

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  4. Changes of micronutrient

    Copper, Zinc, Calcium, Magnesium, Iron, Selenium.

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  5. Changes of sex hormone

    Testosterone, estradiol, luteinizing hormone, prolactin, follicle stimulating hormone, progesterone.

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  6. Changes of Blood lipids

    High density lipoprotein; low density lipoprotein; cholesterol; triglyceride

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  7. Oral glucose tolerance test

    glucose-0,30,120min; C peptide-0,30,120min; insulin-0,30,120min.

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  8. Changes in International Index of Erectile Function-5 scale scores

    minimum point 0, maximum points 25, (≥22 points are normal, 17-21 mild Erectile dysfunction, 12-16 moderateErectile dysfunction, 8-11 moderate Erectile dysfunction, \<7 severe Erectile dysfunction)

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  9. Changes Waist to hip ratio

    Waist to hip ratio(WHR)=waist(cm)/hip(cm)

    Time frame: baseline- 3 months -6 months-12 months-2 years-3years

  10. Semen quality assessment

    Semen quality assessment based the following indicators, including the time of liquefaction, semen PH, semen volume, sperm numbers, sperm vitality, sperm motility, sperm morphology, concentration of zinc in seminal plasma, concentration of fructose in seminal plasma, concentration of neutral α-glucosidase in seminal plasma, concentration of seminal elastase.The corresponding detection method is based on WHO laboratory manual for the Examination and processing of human semen(FIFTH EDITION).

    Time frame: baseline-6 months-12 months-2 years-3years

07

Study locations

1 of 1 sites recruiting
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
    • Shaihong Zhu, M.D. · Contact · leonyi1997@aliyun.com · +86 15802537999
    • Shaihong Zhu, M.D. · Principal investigator
    • Pengzhou Li, M.D. · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04237311
Lead sponsor
The Third Xiangya Hospital of Central South University
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
May 1, 2020
Primary completion
Dec 31, 2021 (estimated)
Completion
Dec 2023 (estimated)
Last update
Mar 11, 2021

Study contacts

Pengzhou Li, M.D.
Contact
lipengzhoulpz@163.com
86-13975878920
Xiang Gao, M.M.
Contact
791902939@qq.com
86-15364008159
Shaihong Zhu, M.D.
principal investigator · Central South University Third Xiangya Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion